Depomed (DEPO): Positive News Flow But There Is Risk If The Company Manages The Sale - RBC
Get access to the best calls on Wall Street with StreetInsider.com's Ratings Insider Elite. Get your Free Trial here.
RBC Capital analyst, Randall Stanicky, reiterated his Sector Perform rating on shares of DepoMed Inc (NASDAQ: DEPO) noting that news flow is about to pick up meaningfully following (i) last week's press report that DEPO may be preparing to put itself up for sale (ii) the 9/19 Starboard letter underscoring its position ahead of the recently set 11/15 shareholder vote and (iii) NUCYNTA legal decision expected by next Fri.
The NUCYNTA decision is expected from Judge Cecchi by Sept 30 (next Fri) and seems likely to add to the company's value. The analyst is most focused on the '364 patent (Dec 2025), which covers both the IR/ER versions (i.e., all NUCYNTA) and is the more debated of the three patents. The analyst believes that absent big surprises any move on a decision is likely worth ~$1.50 to $2.00.
It's unclear if DEPO will have a response to Starboard but the analyst thinks there is risk in the company running a formal sale process. No change to the price target of $22.
Shares of DepoMed Inc closed at $24.22 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Zions Bancorp (ZION) PT Lowered to $49 at FIG Partners Following 4Q EPS Beat
- Jefferies Downgrades NantKwest (NK) to Hold
- Jefferies Reiterastes Hold on McDonald's (MCD) Following 4Q Report
Create E-mail Alert Related CategoriesAnalyst Comments, Analyst EPS View
Related EntitiesRBC Capital
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!